Anna Tomiak

1.3k total citations
17 papers, 404 citations indexed

About

Anna Tomiak is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Anna Tomiak has authored 17 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Anna Tomiak's work include Colorectal Cancer Treatments and Studies (5 papers), Neuroendocrine Tumor Research Advances (4 papers) and Lung Cancer Research Studies (4 papers). Anna Tomiak is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Neuroendocrine Tumor Research Advances (4 papers) and Lung Cancer Research Studies (4 papers). Anna Tomiak collaborates with scholars based in Canada, United States and Japan. Anna Tomiak's co-authors include Mark Vincent, Walter Kocha, Larry Stitt, Pauline T. Truong, Edward Yu, A. Rashid Dar, Gregory M.M. Videtic, Glenn Bauman, Francisco Perera and Eric Winquist and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Anna Tomiak

17 papers receiving 396 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Tomiak Canada 10 259 184 84 78 57 17 404
S. Zonato Italy 11 181 0.7× 128 0.7× 57 0.7× 43 0.6× 29 0.5× 21 375
Beth Eaby United States 8 424 1.6× 180 1.0× 189 2.3× 43 0.6× 71 1.2× 10 665
P. P. A. Razenberg Netherlands 5 210 0.8× 270 1.5× 54 0.6× 65 0.8× 41 0.7× 7 463
Fumihiko Hojo Japan 12 199 0.8× 188 1.0× 82 1.0× 142 1.8× 79 1.4× 20 414
Marta Bonet Spain 12 243 0.9× 141 0.8× 246 2.9× 91 1.2× 36 0.6× 32 483
Rawad Elias United States 10 389 1.5× 159 0.9× 48 0.6× 51 0.7× 42 0.7× 28 535
Kazunari Tateishi Japan 11 269 1.0× 197 1.1× 63 0.8× 57 0.7× 38 0.7× 57 395
Benoît Colinet Belgium 9 193 0.7× 315 1.7× 68 0.8× 50 0.6× 70 1.2× 22 512
C. R. Lazarus United Kingdom 11 70 0.3× 136 0.7× 145 1.7× 93 1.2× 44 0.8× 37 494
Judi van Diessen Netherlands 7 123 0.5× 287 1.6× 31 0.4× 10 0.1× 36 0.6× 14 460

Countries citing papers authored by Anna Tomiak

Since Specialization
Citations

This map shows the geographic impact of Anna Tomiak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Tomiak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Tomiak more than expected).

Fields of papers citing papers by Anna Tomiak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Tomiak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Tomiak. The network helps show where Anna Tomiak may publish in the future.

Co-authorship network of co-authors of Anna Tomiak

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Tomiak. A scholar is included among the top collaborators of Anna Tomiak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Tomiak. Anna Tomiak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Leveridge, Michael, et al.. (2023). Priapism in a Patient with Rectal Adenocarcinoma. SHILAP Revista de lepidopterología. 11(1). 34–34. 2 indexed citations
2.
Leighl, Natasha B., Aurelia Alexandru, Yuichiro Ohe, et al.. (2021). FP04.01 Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907. Journal of Thoracic Oncology. 16(10). S949–S950. 1 indexed citations
3.
Yan, Michael, Cheryl Ho, Eric Winquist, et al.. (2016). Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid. Clinical Colorectal Cancer. 15(4). 369–376.e3. 7 indexed citations
4.
Hazel, Guy A. Van, Dongping Tu, Niall C. Tebbutt, et al.. (2011). Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study.. Journal of Clinical Oncology. 29(15_suppl). 3602–3602. 2 indexed citations
5.
Yu, Edward, Patricia Tai, Jawaid Younus, et al.. (2009). Postoperative Extended-Volume External-Beam Radiation Therapy in High-Risk Esophageal Cancer Patients: A Prospective Experience. Current Oncology. 16(4). 48–54. 14 indexed citations
6.
Yu, Edward, Patricia Tai, Jawaid Younus, et al.. (2007). Post-Operative Extended Volume External Beam Radiation Therapy Is Safe for High Risk Esophageal Cancer Patients. Scholarship@Western (Western University). 1 indexed citations
7.
Videtic, Gregory M.M., Pauline T. Truong, R. Ash, et al.. (2005). Does Sex Influence the Impact That Smoking, Treatment Interruption and Impaired Pulmonary Function Have on Outcomes in Limited Stage Small Cell Lung Cancer Treatment?. Canadian Respiratory Journal. 12(5). 245–250. 14 indexed citations
8.
Yu, Edward, George Rodrigues, Larry Stitt, et al.. (2004). Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients?. Radiotherapy and Oncology. 73(2). 141–148. 15 indexed citations
9.
Videtic, Gregory M.M., Larry Stitt, A. Rashid Dar, et al.. (2003). Continued Cigarette Smoking by Patients Receiving Concurrent Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer Is Associated With Decreased Survival. Journal of Clinical Oncology. 21(8). 1544–1549. 181 indexed citations
10.
11.
Tomiak, Anna, Mark Vincent, Craig C. Earle, et al.. (2001). Thymidylate Synthase Expression in Stage II and III Colon Cancer. American Journal of Clinical Oncology. 24(6). 597–602. 32 indexed citations
12.
Videtic, Gregory M.M., Karen Fung, Anna Tomiak, et al.. (2001). Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer. 33(2-3). 249–258. 39 indexed citations
13.
Tomiak, Anna, Mark Vincent, Walter Kocha, et al.. (2000). Standard Dose (Mayo Regimen) 5-Fluorouracil and Low Dose Folinic Acid: Prohibitive Toxicity?. American Journal of Clinical Oncology. 23(1). 94–98. 27 indexed citations
14.
Tomiak, Anna, G.M. Videtic, A. Rashid Dar, et al.. (2000). Treatment breaks caused by toxicity from concurrent chemoradiation for limited small cell lung cancer decrease survival and local control. International Journal of Radiation Oncology*Biology*Physics. 48(3). 325–326. 2 indexed citations
15.
Fisher, Barbara J., Francisco Perera, Walter Kocha, et al.. (1999). Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. International Journal of Radiation Oncology*Biology*Physics. 45(2). 291–295. 32 indexed citations
16.
Tomiak, Anna, Jonathan C. Yau, S. Huan, et al.. (1994). Duration of intravenous antibiotics for patients with neutropenic fever. Annals of Oncology. 5(5). 441–445. 18 indexed citations
17.
Stewart, David J., S. Gertler, Anna Tomiak, et al.. (1994). High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases. Lung Cancer. 11(3-4). 251–258. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Zonato Breakdown of academic impact, for papers by Beth Eaby Breakdown of academic impact, for papers by P. P. A. Razenberg Breakdown of academic impact, for papers by Fumihiko Hojo Breakdown of academic impact, for papers by Marta Bonet Breakdown of academic impact, for papers by Rawad Elias Breakdown of academic impact, for papers by Kazunari Tateishi Breakdown of academic impact, for papers by Benoît Colinet Breakdown of academic impact, for papers by C. R. Lazarus Breakdown of academic impact, for papers by Judi van Diessen
Rankless by CCL
2026